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Cell activationBackground and aims: Antibody responses to vaccines are suboptimal in immunosuppressed HIV-positive
individuals. This study aimed to evaluate the potential beneﬁts of MF59 adjuvant or a second A/H1N1
inﬂuenza vaccine dose in HIV-positive adults.
Method: HIV-positive adults (n = 61) and HIV-negative controls (n = 93) aged 18–60 years received two
doses of A/H1N1, either as MF59-adjuvanted A/H1N1 pandemic vaccine, or as part of a unadjuvanted sea-
sonal inﬂuenza vaccine containing the pandemic strain. Immunogenicity was assessed against the vac-
cine strain, A/California/7/2009, by haemagglutination inhibition (HI) assay three weeks after the
administration of each vaccine dose. Local and systemic reactions were recorded for three days after each
vaccination. Unsolicited adverse events were recorded throughout the six-week study period.
Results: Both adjuvanted and unadjuvanted vaccines met the European licensure criteria in HIV-positive
and HIV-negative study groups after a single dose. Lower antibody titres were observed with both adju-
vanted and unadjuvanted vaccine in HIV-positive compared to HIV-negative subjects. A second dose of
either vaccine did not compensate for the lower response of HIV-infected subjects. In HIV-positive sub-
jects, CD4+ T cell counts and levels of CD38 expression on CD8+ T cells remained stable throughout the
study period. Both vaccine formulations were generally well tolerated, with no increased reactogenicity
observed in response to the adjuvanted vaccine.
Conclusion: Antibody responses in HIV-positive subjects were acceptable but lower than those in healthy
control subjects, whether subjects were immunized with one or two doses of adjuvanted or unadjuvant-
ed vaccine. Vaccination did not affect rates of HIV replication, CD4+ T cells counts, or levels of CD38
expression among patients under successful antiretroviral treatment.
 2014 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction were prioritized to receive the pandemic vaccine [1,2]. AlthoughWhen immunosuppressed, human immunodeﬁciency virus
(HIV)-positive individuals are at increased risk for inﬂuenza-
related morbidity, and are therefore, among the high-risk groups
recommended to receive seasonal inﬂuenza vaccine on an annual
basis; for similar reasons, during the 2009 A/H1N1 pandemic, theyvaccination against seasonal inﬂuenza has reduced incidences of
inﬂuenza illness, complications, and the overall risk of hospitaliza-
tion in HIV-positive individuals [3,4], antibody responses to vacci-
nation in this population are in general less robust than those seen
in HIV-negative, healthy adults [2,5–8]. HIV-positive individuals
also produced suboptimal antibody responses to pandemic A/
H1N1 inﬂuenza vaccination, which were attributed to various fac-
tors including age, receipt of antiviral therapy, low CD4+ T cell
counts, high viral loads, high baseline antibody titres, and previous
vaccination against seasonal inﬂuenza [9–15]. Of concern, is the
effect of inﬂuenza vaccination on HIV viral replication [16] and less
clear is the effect on T cell activation among individuals under
successful HAART.
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of inﬂuenza vaccines, and in HIV-infected persons, MF59-adju-
vant has provided variably higher antibody titres to seasonal anti-
gens compared with unadjuvanted trivalent inﬂuenza vaccine
(TIV). Since emulsion adjuvants were shown to increase the anti-
body responses to A/H5N1 vaccines, many countries deployed
adjuvanted formulations of A/H1N1 pandemic vaccine. It was not
known at the initiation of clinical trials whether one or two vaccine
doses would be required for HIV-positive subjects. While other
studies have compared responses of HIV-positive and HIV-negative
control subjects to various pandemic vaccines, no other studies to
our knowledge have simultaneously compared responses of both
groups to both unadjuvanted and adjuvanted vaccines containing
A/H1N1 pandemic antigen.
This Phase III, randomized trial evaluated the immunogenicity
and acute safety of monovalent MF59-adjuvanted A/H1N1 pan-
demic inﬂuenza vaccine, and that of an unadjuvanted, seasonal
TIV containing the A/H1N1 pandemic antigen in HIV-positive
adults compared to HIV-negative control subjects. This study also
aimed to identify whether a one- or two-dose vaccination schedule
was most suitable for HIV-infected individuals. Possible vaccine
induced changes in CD4+ T cell counts, viral loads, and the expres-
sion of CD38 on CD8+ T cells were assessed. Immunogenicity was
analysed according to the European licensure criteria for pandemic
inﬂuenza vaccines.2. Materials and methods
2.1 Study design and objectives
This Phase III, randomized, controlled, open-label trial was con-
ducted in HIV-positive and healthy HIV-negative adults, at two
study sites in Brazil between April 2010 and June 2011. This was
the ﬁrst year the H1N1 vaccination was available in Brazil. The pro-
tocol was approved by the Brazilian National Research Ethics Com-
mittee and National Sanitary Surveillance Agency of Brazil. The
trial was carried out in accordance with the Declaration of Helsinki,
Good Clinical Practice guidelines, and local regulatory requirements.
Before enrolment,written informedconsentwasobtained fromeach
participant. The primary objective of this study was to compare the
immunogenicity of twodoses ofMF59-adjuvanted pandemic inﬂu-
enza vaccine compared with two doses of unadjuvanted, split, sea-
sonal inﬂuenza vaccine (2010 southern hemisphere formulation
containing A/California/07/09 [H1N1] antigen) in HIV positive indi-
viduals versus HIV uninfected individuals. HIV uninfected individu-
als were selected to match the same demographic characteristics as
HIV infected individuals. The safety proﬁles of both vaccine formu-
lations were assessed. HIV-positive and HIV-negative subjects were
randomized in equal numbers to receive two doses of either MF59-
adjuvantedA/H1N1vaccine (aH1N1pnd) or unadjuvanted TIV, given
three weeks apart. Blood samples were collected for immunogenic-
ity analysis at baseline (Day 1), and threeweeks after administration
of the ﬁrst (Day 22) and second (Day 43) vaccine doses. HIV-positive
subjects had two additional blood draws on Days 8 and 29 for CD4+
and CD8+ T cell analyses.2.2 Subjects
A total of 61 HIV-positive and 93 HIV-negative adult (18–
60 years) subjects were enrolled. The inclusion criteria for HIV posi-
tive subjects were: conﬁrmed HIV-1 infection; CD4+ T cell count
>200 cells/mm3; HIV-1 viral load <200 copies/mL; no immunomod-
ulatory therapy within three months prior to enrolment; and no
changes in antiviral therapy (including HAART) four weeks prior to
enrolment or planned within three weeks of second vaccination.The exclusion criteria were: laboratory conﬁrmed A/California/7/
2009 (H1N1) inﬂuenza infection; receipt of any vaccine or investiga-
tional agent within three and twelve months of enrolment, respec-
tively; acute febrile illness; allergy to egg or egg protein;
pregnancy; viral load >500 copies/mL within six months prior to
studyenrolment forHIVpositive subjects; a history of cancer (except
for skin cancer); and a history of cognitive or neurological disorders.
2.3 Vaccines
Each 0.5 mL dose of the investigational, MF59-adjuvanted, egg-
derived, monovalent, pandemic inﬂuenza vaccine, Focetria (Nov-
artis Vaccines and Diagnostics, Siena, Italy; Lot.091001), contained
7.5 lg of A/California/7/2009 (H1N1) haemagglutinin and a stan-
dard quantity of MF59 adjuvant (9.75 mg squalene, 1.18 mg poly-
sorbate 80, 1.18 mg sorbitan trioleate, 0.66 mg sodium citrate
dehydrate, and 0.04 mg citric acid monohydrate). One 0.5 mL dose
of the unadjuvanted, seasonal, trivalent, inﬂuenza vaccine, Begri-
vac (Novartis Vaccines and Diagnostics, Marburg, Germany; Lot
226011C), contained 15 lg of antigen from each of the WHO rec-
ommended viral strains for the 2010–11 inﬂuenza season (south-
ern hemisphere): A/California/7/2009 (H1N1), A/Perth/16/2009
(H3N2), and B/Brisbane/60/2008. Vaccines were supplied in pre-
ﬁlled, monodose-syringes and were administered intramuscularly
in the deltoid muscle of the non-dominant arm.
2.4 Immunogenicity analysis
Blood samples of 10–15 mL and 10–25 mL were collected from
HIV-negative and HIV-positive subjects, respectively. Sera were
stored at 18 C and shipped to the Novartis Vaccines Clinical
Serology Laboratory in Marburg, Germany, where antibody
responses were assessed by haemagglutination inhibition (HI)
assay against the A/H1N1 pandemic vaccine antigen strain only.
The HI assay was based on the method of Stephenson and col-
leagues [15]. HI titre was expressed as the reciprocal of the highest
dilution at which haemagglutination was totally inhibited. Sero-
conversion was deﬁned as a negative pre-vaccination antibody
titre of <10 to a positive post-vaccination titre of P40, or as a
P4-fold increase in subjects seropositive (titre P10) at baseline.
HI titres below the detection limit of 10 were arbitrarily assigned
to half that limit for the purpose of analysis.
2.5 Safety analysis
Subjects were observed for a minimum of 30 min after each vac-
cination to monitor for any possible immediate adverse reactions.
Solicited local and systemic reactions were recorded in diary cards
for three days after each vaccination. Local reactions included pain,
and swelling or redness at the site of injection. Systemic reactions
included fever (>37.5 C), headache, muscle pain, irritability, sleep-
iness, loss of appetite, nausea, vomiting, urticaria, and rhinorrhea.
All unsolicited adverse events (AEs), including serious adverse
events (SAEs) and AEs of special interest (neuritis, seizures, severe
allergic reactions, angioedema, non-infectious encephalitis, vascu-
litis, Guillain-Barré syndrome, demyelination, and Bell’s palsy),
were recorded throughout the entire study period (Day 1–43).
2.6 HIV-1 viral loads, CD4+ T cell counts, and CD38 expression on CD8+
T cells
HIV-1 viral loads were quantiﬁed on study Days 1, 8, 21, 29 and
43 by real-time reverse transcriptase polymerase chain reaction
(RealTime HIV-1 assay; Abbott Diagnostics, IL, USA). CD4+ T cell
counts, and the analysis of CD38 expression on CD8+ T cells was
performed in HIV-positive subjects only on study Days 1, 8, 21,
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using Cellquest software. Peripheral Blood Mononuclear Cells
(PBMCs) were ﬁxed (FACS Lysing Solution, BD Bioscience), perme-
abilized (FACS Permeabilization Buffer, BD Bioscience), and stained
with anti-CD4:FITC, anti-CD38:PE, and anti-CD8:PerCP monoclonal
antibodies (all Pharmingen).
2.7 Statistical analysis
Statistical analyses were performed within and across vaccine
groups. Safety results were evaluated descriptively. Immunogenic-
ity endpoints were evaluated based on criteria for pandemic inﬂu-
enza vaccines established by the EU Committee for Medicinal
Products for Human Use (CHMP): the percentage of subjects
achieving seroconversion for HI antibody should be P40%; geo-
metric mean ratios (GMRs) should be >2.5; and to achieve seropro-
tection, the percentage of subjects achieving an HI antibody titre
P40% should be >70%. Two-sided 95% CIs were calculated accord-
ing to the Clopper Pearson method. Immunogenicity results were
logarithmically transformed (base10) prior to analysis and
responses were adjusted for baseline antibody status.3. Results
Of the total participants enrolled, 90% and 91% of subjects in the
aH1N1pnd and TIV vaccination groups completed the study on Day
43, respectively. The primary reasons for subjects not completing
the study were their withdrawal of consent and being lost to fol-
low-up. Subject disposition and study design are illustrated in
Fig. 1. The age and body mass index of subjects in the aH1N1pnd
and TIV vaccination groups and between HIV infected and non-
infected were similar. The majority of subjects were Caucasian.
Study populations demographics are presented in Table 1. Full
Analysis Set (FAS) immunogenicity data are reported throughout.
3.1 Immunogenicity
Baseline HI geometric mean antibody titres (GMTs) were low in
all four vaccination groups, ranging from 12 to 18 (Table 2). Three
weeks after the administration of the ﬁrst dose of either vaccine
(Day 22), GMTs, the proportion of subjects achieving a seroprotec-
tive titre and those who had seroconverted were higher in the HIV-
negative compared with the HIV-positive cohort (Table 2, Fig. 2). A
second vaccine dose did not restore GMTs of HIV-infected subjects
to the level of those seen in HIV-negative subjects. However, after
two doses of the adjuvanted vaccine, 100% of HIV-infected subjects
achieved seroprotective antibody titres of 40 or higher, as did all
HIV uninfected subjects, while a lower proportion (90%) of HIV-
infected subjects receiving unadjuvanted vaccine were seropro-
tected after two doses.
After theﬁrst doseof theMF59-adjuvantedvaccine, a greaterpro-
portion of HIV-infected subjects seroconverted (79%) compared to
unadjuvanted vaccine recipients (68%). Similarly, in HIV-negative
subjects, 85% of adjuvanted vaccine recipients seroconverted, versus
76% of those receiving unadjuvanted vaccine. The adjuvanted vac-
cine also provided a higher level of seroprotection after one dose in
HIV-infected subjects (93%) than unadjuvanted vaccine (87%). All
three CHMP licensure criteria were met by HIV-positive and HIV-
negative cohorts in response to twodoses of either aH1N1pnd or TIV.
3.2 HIV viral loads, CD4+ T cell counts, and CD38 expression on CD8+ T
cells
In the HIV-positive study groups receiving aH1N1pnd and TIV,
HIV-1 viral loads remained below the limit of detection(<40 copies/mL) over the entire six-week study period. CD4+ T cell
counts in HIV-positive subjects receiving aH1N1pnd and TIV were
performed on study Days 1, 8, 22, 29 and 43 (Fig. 3). Vaccination
with aH1N1pnd or TIV had no effect on CD4+ T cell counts relative
to baseline values, with similar cell numbers observed following
vaccination with ﬁrst and second doses of adjuvanted and unadju-
vanted vaccine. In the aH1N1pnd study group, mean CD4+ T cell
counts ranged from 562 cells/mm3 on Day 1 to 582 cells/mm3 on
Day 43. In subjects receiving TIV, mean cell counts ranged from
527 cells/mm3 on Day 1 to 609 cells/mm3 on Day 43. As a marker
of inﬂammation and immune activation, levels of CD38 expression
on CD8+ T cells were assessed in HIV-positive subjects by ﬂow
cytometry (Fig. 4). Vaccination with aH1N1pnd or TIV had no affect
on levels of CD8+ T cell CD38 expression relative to baseline values.
Similar levels of CD38 were detected following vaccination with
ﬁrst and second doses of adjuvanted and unadjuvanted vaccines.
Over the course of the study, the mean ﬂuorescence intensity
(MFI) of cell surface CD38 expression ranged from 102 (Day 1) to
163 (Day 43) in the aH1N1pnd group, and from 82 (Day 1) to
171 (Day 43) in the TIV group.3.3 Safety
The percentages of subjects with treatment emergent AEs were
similar in the HIV-positive and HIV-negative cohorts. The percent-
ages of subjects with AEs were slightly higher in the adjuvanted
(93.4%) compared with the unadjuvanted (88.3%) vaccine groups
(Table 3). The most frequent local reaction was mild to moderate
pain at the site of injection, experienced by similar percentages
of HIV-positive subjects in the aH1N1pnd (55.2%) and TIV (56.3%)
vaccination groups. In the HIV-negative cohort, 66% and 62% of
subjects reported pain in aH1N1pnd and TIV groups, respectively.
Overall, there was a trend towards less reactogenicity after the sec-
ond vaccine dose. The majority of solicited local and systemic reac-
tions were of mild to moderate severity, with 7.2% of both HIV-
positive and HIV-negative subjects experiencing severe reactions
across ﬁrst and second doses. No cases of fever (>37.5 C) or AEs
of special interest occurred within any vaccination group during
the study. Non-vaccine-related SAEs were experienced by one
HIV positive subject in the aH1N1pnd vaccination group, and one
HIV-negative subjects receiving TIV. Two SAEs (gingival bleeding
and panniculitis) considered to be at least possibly related to TIV
occurred in one HIV-negative subject (Table 3). No subjects were
withdrawn from the study due to AEs.4 Discussion
This study was performed to determine whether MF59-adju-
vanted, A/H1N1 pandemic vaccine was more immunogenic in
HIV-positive subjects than unadjuvanted vaccine. Although a sin-
gle dose of either adjuvanted or unadjuvanted vaccine was sufﬁ-
cient to meet all three CHMP licensure criteria in both HIV-
positive and control HIV-negative cohorts, the adjuvanted vaccine
led to seroconversion in 10%more of both subjects in both groups
compared to unadjuvanted vaccine. In addition, after the ﬁrst dose
seroprotection was achieved in 6% more of HIV-infected subjects
who received the adjuvanted vaccine. Overall it was clear that
the responses of HIV-positive subjects were reduced compared
with those of HIV-negative controls. A second dose of either vac-
cine did not lead to signiﬁcantly increased antibody titres in HIV-
infected or non-infected subjects, and did not compensate for the
difference between the responses of HIV-infected and healthy sub-
jects. Both vaccine formulations were generally well tolerated,
with similar safety proﬁles observed in HIV-positive and HIV-neg-
ative subjects. No increase in reactogenicity was observed in
Total subjects enrolled
(N = 154)
HIV Positive
H1N1-MF59
(n = 29)
HIV Positive
TIV
(n = 32)
HIV Negative
H1N1-MF59
(n = 47)
HIV Negative
TIV
(n = 46)
Day 1
- Baseline immunogenicity analysis
- Vaccine Dose 1
Day 22
- Post-Dose 1 immunogenicity analysis
- Vaccine Dose 2
Day 43
- Post-Dose 2 immunogenicity analysis
Subjects completing study on Day 43
n = 27 (93%)
- WC: n = 1 (3.5%)
- LTF: n = 1 (3.5%)
n = 31 (97%)
- IE: n = 1 (3.1%)
n = 41 (87%)
- WC: n = 3 (6.4%)
- LTF: n = 2 (4.3%)
- Other: n = 1 (2.1%)
n = 40 (87%)
- WC: n = 2 (4.3%)
- LTF: n = 4 (8.7%)
WC, withdrew consent; LTF, lost to follow-up; IE, inappropriate enrolment 
Fig. 1. Study design. A total of 61 HIV-positive and 93 HIV-negative control subjects were enrolled in the study. Subjects received two doses of either MF59-adjuvanted, A/
H1N1 pandemic inﬂuenza vaccine (aH1N1pnd), or two doses of unadjuvanted, trivalent, seasonal inﬂuenza vaccine (TIV). Immunogenicity was assessed by
haemagglutination inhibition (HI) assay three weeks after immunization.
Table 1
Baseline demographics of enrolled study populations.
aH1N1pnd
(n = 76)
TIV
(n = 77)
Mean age (years, SD) 42.6 (9.1) 42.0 (10.4)
Males (%) 46 61
Mean weight (kg, SD) 71.4 (15.4) 72.9 (14.4)
Mean height (cm, SD) 165.5 (9.9) 168.9 (9.0)
Mean BMI (kg/m2, SD) 25.8 (3.8) 25.5 (4.6)
Previous inﬂuenza vaccine (%) 27.6 33.8
Former smoker (%) 30.3 24.7
Current smoker (%) 17.1 18.2
Caucasian (%) 75.0 83.1
Black (%) 6.6 6.5
Asian (%) 2.6 3.9
Mixed race (%) 15.8 6.5
BMI, body mass index.
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that the open label nature of the study and the absence of a control
group may have inﬂuenced the description of symptoms related to
the safety proﬁle.In general, the administration of a second dose of unadjuvanted
pandemic or seasonal vaccine in HIV positive adults has not been
successful in overcomingpoor responses to the initial dose, although
exceptions have been reported [17–19]. As reported in previous
studies, we found a moderate increase in antibody levels following
a second dose of MF59-adjuvanted A/H1N1 pandemic vaccine
[12,20]. Some, but not all studies, have described similar results
for AS03-adjuvanted vaccine [9,19,21]. Interestingly, doubling the
antigen content of unadjuvanted subunit pandemic vaccine, from
15 to 30 lg, provided signiﬁcantly better responses in HIV-infected
subjects, although, their responses still fell below those of normal
subjects [22]. Seroprotection rates have been reported to decline
more rapidly in HIV-positive than HIV-negative individuals receiv-
ing unadjuvanted pandemic vaccine [10,20]. In studies of antibody
persistence following adjuvanted and unadjuvanted A/H1N1 and
A/H5N1 vaccination in healthy subjects, antibody titres to the adju-
vanted formulationsweremaintained at higher levels up to one year
later [23–28]. These data and other studies [13,18,29–31] suggest
that an adjuvant may help maintain protection during the course
of extended transmission during outbreaks.
Table 2
Immunogenicity analysis (95% CI) by haemagglutination inhibition (HI) assay against the A/California/7/2009 (H1N1) vaccine strain at baseline (Day 1), and three weeks after the
administration of ﬁrst (Day 22) and second (Day 43) vaccine doses.
HIV-positive HIV-negative
aH1N1pnd TIV aH1N1pnd TIV
Geometric mean titre
Day 1 12 (7–21)
(n = 29)
17 (10–29)
(n = 32)
13 (8–21)
(n = 47)
18 (11–29)
(n = 44)
Day 22 288 (152–547)
(n = 28)
415 (226–763)
(n = 31)
682 (476–975)
(n = 47)
826 (570–1196)
(n = 45)
Day 43 410 (240–700)
(n = 28)
370 (223–615)
(n = 31)
785 (572–1076)
(n = 42)
696 (509–951)
(n = 44)
Geometric mean ratio
Day 22:Day 1 22 (10–47)
(n = 28)
25 (12–50)
(n = 31)
52 (30–90)
(n = 47)
47 (27–83)
(n = 44)
Day 43:Day 1 31 (16–60)
(n = 28)
22 (12–41)
(n = 31)
59 (34–101)
(n = 42)
39 (23–66)
(n = 43)
% Seroconversion or P4-fold increase
Day 22 79 (59–92)
(n = 28)
68 (49–83)
(n = 31)
85 (72–94)
(n = 47)
76 (61–87)
(n = 45)
Day 43 79 (59–92)
(n = 28)
71 (52–86)
(n = 31)
86 (72–95)
(n = 42)
84 (70–93)
(n = 44)
Fig. 2. Seroprotection rates among HIV-positive and HIV-negative subjects three weeks after ﬁrst (Day 22) and second (Day 43) vaccine doses. Broken line represents the
CHMP licensure criterion for seroprotection.
Fig. 3. Mean (±SD) CD4+ T cell counts in HIV-positive subjects at baseline (Day 1), one (Day 8) and three (Day 22) weeks after ﬁrst, and one (Day 29) and three (Day 43) weeks
after second aH1N1pnd or TIV vaccine doses.
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TIV containing the A/H1N1 pandemic strain rather than a unadju-
vanted, monovalent, pandemic vaccine as a control, which was
unavailable when the study commenced. Although the TIVcomparator contained the same pandemic viral strain with the
usual quantity (15 lg) of viral haemagglutinin, the antigen was
derived from split virions, while the monovalent pandemic vaccine
contained puriﬁed haemagglutinin subunits. As responses to split
Fig. 4. Mean ﬂuorescence intensity (MFI) of CD38 expression (±SD) on CD8+ T cells in HIV-positive subjects, as measured by ﬂow cytometry at baseline (Day 1), one (Day 8)
and three (Day 22) weeks after ﬁrst, and one (Day 29) and three (Day 43) weeks after second aH1N1pnd or TIV vaccine doses.
Table 3
Percentages of subjects experiencing adverse events throughout the entire study period (Day 1–43).
HIV-positive HIV-negative
aH1N1pnd
(n = 29)
TIV
(n = 32)
aH1N1pnd
(n = 47)
TIV
(n = 45)
Adverse events (%) 93 88 94 89
Vaccine-related adverse events (%) 72 69 77 76
Severe adverse events (%) 7 6 9 7
Serious adverse events (%) 3 0 0 4
R.S. Diaz et al. / Trials in Vaccinology 3 (2014) 114–120 119antigens are, in general, similar to or higher than those to subunit
TIVs, differences between the responses to adjuvanted and unadju-
vanted vaccines in the trial would have tended toward an underes-
timation of the adjuvant’s effect. A limitation of many other trials
of A/H1N1 pandemic vaccines was the potential for acquired pan-
demic infections to interfere with interpretation of the immune
response to vaccination; this was unlikely in our study, which
was completed in June while the peak of the pandemic in southern
Brazil was in early August.
It is conceivable that vaccination could transactivate HIV and
transiently increase the viral load [32,33] with the potential risk
of antiretroviral resistance [34], which has not been observed in
the current study. The expression of CD38 on the surface of CD8+
T cells is indicative of cellular activation, and in HIV-positive indi-
viduals, correlates with plasma viremia and CD4+ T cell numbers;
levels of CD8+ T cell CD38 expression are also reported to reliably
predict the onset of acquired immunodeﬁciency syndrome (AIDS)
– particularly in patients receiving antiretroviral therapy [35–41],
blunted CD4+ T cell recovery [33,42] and non-AIDS clinical out-
comes [43]. Vaccination had no impact on levels of CD38 expres-
sion, or CD4+ T cell numbers over the course of this study. The
six-week observational period of this trial was insufﬁcient to ade-
quately monitor possible changes in CD4+ T cells numbers and lev-
els of CD38 expression resulting from vaccination. A prolonged
investigation over twelve months is required to fully assess the
effects of adjuvanted versus unadjuvanted vaccination on T lym-
phocyte numbers and phenotype. An extended study would also
allow for comprehensive analysis of the possible beneﬁts of
MF59 adjuvant on long-term antibody persistence in immunosup-
pressed HIV-positive individuals. The relatively high CD4+ T cell
counts and low viral loads of the HIV-positive subjects enrolled
in this trial suggest that these individuals were not immunocom-
promised and were essentially in good health. Therefore, HIV-posi-
tive subjects were able to respond well to the unadjuvanted
vaccine. Further studies involving severely immunosuppressedsubjects, with higher viral loads and lower CD4+ T cell counts,
are required to determine whether MF59-adjuvanted vaccine
may be of signiﬁcant beneﬁt to immunosuppressed HIV-positive
individuals.
In conclusion, well-controlled HIV-infected patients on retrovi-
ral therapy responded adequately but less well to the A/H1N1 pan-
demic vaccine than healthy control subjects, whether antigen was
in the form of a routine, unadjuvanted, seasonal vaccine or in an
MF59-adjuvanted, monovalent, A/H1N1 pandemic formulation. A
second dose of either vaccine did not compensate for the relatively
lower response in HIV positive subjects. All vaccinations were well
tolerated and did not affect viral loads, CD4+ T cell counts, or levels
of CD38 expression on CD8+ T cells.Author contributions
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